|
Delayed
Bombay S.E.
07:29:55 30/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2,665.40 INR | -2.84% |
|
-4.51% | +44.76% |
| 09-25 | Caplin Point Laboratories Limited Approves Appointment of D Muralidharan as Whole Time Director | CI |
| 08-14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 2,765 | +0.79% | 2 | |||||
| 2,175.59 | +16.65% | 32 | ||||||
| 14,933.33 | +30.99% | 12 | ||||||
| 1,197.45 | -0.25% | 30 | ||||||
| 1,509.08 | +9.41% | 36 | ||||||
| 257.83 | -0.83% | 6 | ||||||
| - | 2,508.33 | +7.49% | 12 | |||||
| 13,214.57 | +7.17% | 7 | ||||||
| 2,497.73 | +2.3% | 11 | ||||||
| - | - | - | - | - | ||||
| 3,796.46 | +6.72% | 13 | ||||||
| 172.67 | +7.25% | 3 | ||||||
| 16.62 | +70.96% | 3 | ||||||
| - | - | - | - | - | ||||
| - | - | 133.12 | +5.65% | 2 | ||||
| - | 153.75 | +17.9% | 5 | |||||
| - | - | 14.6 | +10.86% | 1 | ||||
| Average | 3,023.08 | +12.87% | 12 | ||||||
| Weighted average by Cap. | 5,315.5 | +16.05% | 19 |
Select your edition
All financial news and data tailored to specific country editions
